Pulmatrix, Inc., a clinical stage biopharmaceutical company, develops inhaled therapies for the treatment, prevention, and transmission control of infectious and progressive respiratory diseases. It offers inhaled cationic airway lining modulator drugs, which stimulate host defense mechanisms within the airway to treat and prevent influenza, rhinovirus, and chronic pulmonary diseases. The company was founded in 2003 and is based in Lexington, Massachusetts.
Current Team (9)Update
Director Quality Assurance and Project Management
CEO & Board of Directors
Sr. Director Aerosol Science and Intellectual Property
Chief Scientific Officer
Founder & Board of Directors
Director Regulatory Affairs and Clinical Operations
Past Team (5)Update
Funding Rounds (5) - $73.9MUpdate
Board Members and Advisors (11)Update
Polaris Partners is a venture company investing in digital media, life sciences, and enterprise...
ARCH invests primarily in companies co-founded with leading scientists and entrepreneurs,...
Venture capital Firm
99 Hayden Avenue
Lexington, MA 02421